[Critical state medicine. Surfactant therapy of adult respiratory distress syndrome (results of multicenter studies)].
The paper provides evidence for the pathogenetic approach to treating acute lung lesion (ALL) and adult respiratory distress syndrome (ARDS). An algorithm of the use of Russian lung surfactant preparations: CT-HL and CT-BL has been developed. In involves earlier (the first days following the onset of respiratory failure) use of surfactant, its combined bolus intratracheal or intrabronchial administration in doses of 200-400 mg/m2, followed by continuous (5-day) aerosol inhalation in doses of 20-30 mg/h for children and 30-75 mg/h for adults until pronounced clinical and X-ray effects are shown. Fifty three patients were found to develop ALL and ARDS in the presence of severe pneumonia, postperfusion lung disorders, reperfusion syndrome, pulmonary embolism, long-term artificial ventilation, combined car accident injury and gunshot wounds of the chest, heroine intoxication, septic shock, sepsis, postoperative sequels in cancer patients, and after hepatic transplantation or massive aspiration of gastric contents. Fifty patients were overcome their critical status, 44 survived. The duration of artificial ventilation (AV) ranged from 1 to 6 days. Earlier use of the drugs made it possible to transfer patients to safe AV regimens and to eliminate ALL and ARDS rapidly and to significantly reduce mortality due to critical states.
Granov
A M
AM
Rozenberg
O A
OA
Tsybul'kin
E K
EK
Erokhin
V V
VV
Khubulava
G G
GG
Likhvantsev
V V
VV
Osovskikh
V V
VV
Bautin
A E
AE
Gavrilin
S V
SV
Kazennov
V V
VV
Zhilin
Iu N
IuN
Nabokova
T S
TS
Shefer
S P
SP
Vashkevich
S M
SM
Nefedov
A V
AV
Seĭliev
A A
AA
Volchkov
V A
VA
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000465:Algorithms; D002648:Child; D002675:Child, Preschool; D003422:Critical Care; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000188:drug therapy / Q000628:therapy; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D012120:Respiration Disorders / Q000188:drug therapy / Q000628:therapy; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D012138:Respiratory Therapy; D013997:Time Factors
D011663:Pulmonary Surfactants
Meditsina kriticheskikh sostoianiĭ. Surfaktant-terapiia respiratornogo distress-sindroma vzroslykh (rezul'taty mnogotsentrovykh ispytaniĭ).